{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:09:47Z","timestamp":1756634987665,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018170","name":"Fondation Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03246-z","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:26:06Z","timestamp":1748579166000},"page":"3011-3019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tabelecleucel in Post-transplant Epstein\u2013Barr Virus-Associated Lymphoproliferative Disease: Patient and Oncologist Perspectives"],"prefix":"10.1007","volume":"42","author":[{"given":"Antonio","family":"Perez-Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anarbella","family":"Lastra Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Ramos Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Gonzalez Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida","family":"Alcolea S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Hernandez Oliveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"1","key":"3246_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41409-023-02127-9","volume":"59","author":"G Soci\u00e9","year":"2023","unstructured":"Soci\u00e9 G, Barba P, Barlev A, Sanz J, Garc\u00eda-Cadenas I, Chevallier P, et al. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. Bone Marrow Transplant. 2023;59(1):52\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3246_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","volume":"8","author":"Z Al-Mansour","year":"2013","unstructured":"Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173\u201383. https:\/\/doi.org\/10.1007\/s11899-013-0162-5.","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"3246_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549\u201362. https:\/\/doi.org\/10.1056\/NEJMra1702693.","journal-title":"N Engl J Med"},{"issue":"1","key":"3246_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"3246_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/TP.0b013e318269e64f","volume":"94","author":"D Glotz","year":"2012","unstructured":"Glotz D, Chapman JR, Dharnidharka VR, Hanto DW, Castro MCR, Hirsch HH, et al. The seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation. 2012;94(8):784\u201393.","journal-title":"Transplantation"},{"issue":"3","key":"3246_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/TP.0b013e318276a237","volume":"95","author":"M Morton","year":"2013","unstructured":"Morton M, Coupes B, Roberts SA, Klapper PE, Byers RJ, Vallely PJ, et al. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Transplantation. 2013;95(3):470\u20138.","journal-title":"Transplantation"},{"issue":"2","key":"3246_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajh.21911","volume":"86","author":"SC Quinlan","year":"2011","unstructured":"Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in U.S. Kidney Recipients. Am J Hematol. 2011;86(2):206.","journal-title":"Am J Hematol"},{"issue":"11","key":"3246_CR8","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","volume":"54","author":"D Dierickx","year":"2013","unstructured":"Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433\u201340. https:\/\/doi.org\/10.3109\/10428194.2013.780655.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3246_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, Velden WVD, Fox CP, Engelhard D, La Camara RD, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803\u201311.","journal-title":"Haematologica"},{"issue":"5","key":"3246_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3109\/0284186X.2013.844853","volume":"53","author":"A Kinch","year":"2014","unstructured":"Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, et al. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014;53(5):669\u201379.","journal-title":"Acta Oncol"},{"issue":"12","key":"3246_CR11","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","volume":"8","author":"S Nikiforow","year":"2024","unstructured":"Nikiforow S, Whangbo JS, Reshef R, Tsai DE, Bunin N, Abu-Arja R, et al. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024;8(12):3001\u201312.","journal-title":"Blood Adv"},{"key":"3246_CR12","unstructured":"SEHH. Informe de Posici\u00f3n de la SEHH -Tabelecleucel-Ebvallo. 26 June 2023. Available from: https:\/\/www.sehh.es\/publicaciones\/informes-de-posicion-de-la-sehh-ips\/125601-tabelecleucel-ebvallo-en-el-tratamiento-de-enfermedad-linfoproliferativa-postrasplante-asociada-al-virus-de-epstein-barr-elpt-veb-en-recaida-o-refractaria."},{"key":"3246_CR13","unstructured":"Ebvallo (tabelecleucel) Summary of Product Characteristics. [Internet]. Pierre Fabre; 2022 [cited 2023 Jun 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ebvallo-epar-product-information_en.pdf."},{"key":"3246_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1083215","author":"K Al-Akioui Sanz","year":"2023","unstructured":"Al-Akioui Sanz K, Echecopar Parente C, Ferreras C, Men\u00e9ndez Ribes M, Navarro A, Mestre C, et al. Familial CD45RA- T cells to treat severe refractory infections in immunocompromised patients. Front Med (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1083215.","journal-title":"Front Med (Lausanne)"},{"key":"3246_CR15","unstructured":"BOE. Real Decreto 1015\/2009, de 19 de junio, por el que se regula la disponibilidad de medicamentos en situaciones especiales. BOE N\u00fam. 174 [Internet]. 2009 [cited 2024 Jun 28]. Available from: https:\/\/www.boe.es\/boe\/dias\/2009\/07\/20\/pdfs\/BOE-A-2009-12002.pdf"},{"issue":"3","key":"3246_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110793","volume":"85","author":"M Sykes","year":"2024","unstructured":"Sykes M. Tolerance in intestinal transplantation. Hum Immunol. 2024;85(3): 110793.","journal-title":"Hum Immunol"},{"key":"3246_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","author":"A Par\u00eds-Mu\u00f1oz","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, Udaondo C, Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B, et al. CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100676.","journal-title":"Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03246-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:47Z","timestamp":1750493687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03246-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03246-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio P\u00e9rez Mart\u00ednez, Anarbella Lastra Rodrigo, Esther Ramos Boluda, Berta Gonz\u00e1lez Martinez, Alida Alcolea S\u00e1nchez and Francisco Hernandez Oliveros declare that they have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Participants were informed about the objectives of the study, and written informed consent for publication was obtained before the article was drafted. All authors approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}}]}}